Dec 2025 (FY25) — Feb 5, 2026
Novo Nordisk FY25 — Strong GLP-1 Growth and Wegovy Pill Launch Amidst 2026 Pricing Headwinds
Read the full callNovo Nordisk (NVO) earnings
- Dec 2025 (FY25)
- Dec 2025
Novo Nordisk earnings: last reported Thu, 5 Feb 2026, for the quarter ended Dec 2025.
Price
$38.42 −1.06% · −$0.41
Performance −29.3% 1Y
1Y: $54.37 on 17 Oct 2025 → $38.42. High $63.98 (26 Jan 2026), low $35.29 (30 Mar 2026).
- Previous close
- $38.83
- 52-week range
- $35.29 – $63.98
- One year
- −31.07%
Overview
- Symbol
- NVO
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- US
- Currency
- USD
Call summaries
Sep 2025 (Q3 FY25) — Nov 5, 2025
Novo Nordisk Q3 FY25 — Strategic Refocus and Pipeline Expansion Amidst Competitive Headwinds
Read the full callJun 2025 (Q2 FY25) — Aug 6, 2025
Novo Nordisk Q2 FY25 — Strong H1 GLP-1 Growth Tempered by Revised Full-Year Outlook
Read the full callEvery analysed call
Novo Nordisk earnings calls (NVO)
Financials
What the filings say
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 9,036 | 10,227 | 13,456 | 18,849 | 22,629 | 30,827 | 44,875 | 54,882 |
| Fixed assets | 6,424 | 7,601 | 8,290 | 8,432 | 9,563 | 13,486 | — | — |
| Total assets | 16,985 | 18,887 | 23,899 | 29,624 | 34,603 | 46,626 | 64,862 | 85,409 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 6,841 | 7,034 | 8,567 | 8,377 | 11,315 | 16,147 | 16,851 | 18,737 |
| Cash from investing | -1,852 | -1,730 | -3,700 | -4,813 | -3,574 | -6,507 | -17,955 | -12,453 |
| Cash from financing | -5,293 | -5,335 | -5,317 | -3,883 | -7,429 | -9,364 | 1,217 | -4,469 |
| Capital expenditure | -1,478 | -1,343 | -961 | -965 | -1,742 | -3,826 | -6,570 | -9,461 |
| Free cash flow | 5,364 | 5,691 | 7,607 | 7,412 | 9,573 | 12,321 | 10,281 | 9,276 |
NVO operating KPIs by quarter
| KPI | Jun 2025 Q2 FY25 | Sep 2025 Q3 FY25 | Change vs prior quarter |
|---|---|---|---|
| Patients Diabetes and obesity | <46MStarting with our focus on purpose and sustainability, we are now serving almost 46 million patients with our diabetes and obesity treatments.Source: earnings call transcript | ~46MWe're now serving around 46 million people living with diabetes and obesity.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
No filings in the last 12 months.
No officer, director or 10% owner of NVO filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for NOVO NORDISK A S
Free account. Everything above stays public.
Write why you follow NOVO NORDISK A S and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading